Expertise in
5
conditions

Kye Y. Lee

Nung-dong, KR 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
5
conditions
Nung-dong, KR 
OverviewLocationsClinical Research

Overview

Kye Lee practices in Nung-dong, Republic of Korea. Mr. Lee is highly rated in 5 conditions, according to our data. His top areas of expertise are EGFR Positive Lung Cancer, Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Lung Adenocarcinoma, and Tissue Biopsy.

His clinical research consists of co-authoring 67 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years.

Gender
Male

Locations

Nung-dong, Republic of Korea
Other Locations
Seoul, Republic of Korea
Busan, Republic of Korea

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A Phase II, Multicenter Study of Lazertinib as Consolidation Therapy in Patients With Locally Advanced, Unresectable, EGFR Mutation Positive Non-Small Cell Lung Cancer (Stage III) Who Have Not Progressed Following Definitive, Platinum-based, Chemoradiation Therapy (PLATINUM Trial)
A Phase II, Multicenter Study of Lazertinib as Consolidation Therapy in Patients With Locally Advanced, Unresectable, EGFR Mutation Positive Non-Small Cell Lung Cancer (Stage III) Who Have Not Progressed Following Definitive, Platinum-based, Chemoradiation Therapy (PLATINUM Trial)
Enrollment Status: Recruiting
Publish Date: September 01, 2023
Intervention Type: Drug
Study Phase: Phase 2
Retreatment With 1st Generation EGFR TKIs in Sensitizing EGFR Mutation Positive Non-Squamous Cell Carcinoma Patients Who Previously Treated With EGFR TKI and Cytotoxic Chemotherapy
Retreatment With 1st Generation EGFR TKIs in Sensitizing EGFR Mutation Positive Non-Squamous Cell Carcinoma Patients Who Previously Treated With EGFR TKI and Cytotoxic Chemotherapy
Enrollment Status: Unknown
Publish Date: July 15, 2021
Intervention Type: Drug
Study Drug: EGFR
Study Phase: Phase 2
A Phase II Study to Assess Efficacy of Pan-HER Inhibitor (HM781-36B, Poziotinib) in Stage IV Lung Adenocarcinoma With HER2 Mutation
A Phase II Study to Assess Efficacy of Pan-HER Inhibitor (HM781-36B, Poziotinib) in Stage IV Lung Adenocarcinoma With HER2 Mutation
Enrollment Status: Completed
Publish Date: May 24, 2018
Intervention Type: Drug
Study Phase: Phase 2
View 2 Less Clinical Trial

67 Total Publications

Recent Advances in PET and Radioligand Therapy for Lung Cancer: FDG and FAP.
Recent Advances in PET and Radioligand Therapy for Lung Cancer: FDG and FAP.
Journal: Cancers
Published: June 30, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Lee's expertise for a condition
ConditionClose
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile